GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey
Executive Summary
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
You may also be interested in...
GSK Reorganizes Around Key R&D Areas As Lepore Exits
The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
US FDA Pushes Back GSK’s Momelotinib Decision
GSK remains confident of approval despite the delay, with hopes of blockbuster sales for its myelofibrosis candidate.